Skip to Main Content

Paper Details

[<sup>18</sup>F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial.
BMJ Open
7
2020
Author NameAffiliation
Rachel M GlicksmanUniversity of Toronto
Neil E FleshnerUniversity Health Network, University of Toronto
Robert G BristowUniversity of Manchester Cancer Research UK Manchester Institute and Manchester Cancer Research Centre The Christie NHS Foundation Trust
Antonio FinelliUniversity Health Network, University of Toronto
  • 1 - 4

Datasets

Release 1.2